Personalized Acromegaly Treatment System with AI, IoT, and Blockchain Integration
Legal Citation
Summary of the Inventive Concept
A novel system integrating AI-driven dosage calculation, IoT-enabled wearables, and blockchain-based patient data management to optimize treatment outcomes for acromegaly patients
Background and Problem Solved
The original patent relates to oral drug delivery of octreotide for treating acromegaly. However, it has limitations in terms of personalized treatment, real-time monitoring, and secure data management. The new inventive concept addresses these limitations by introducing AI, IoT, and blockchain technologies to create a more effective and efficient treatment system
Detailed Description of the Inventive Concept
The system comprises an AI-driven dosage calculator that analyzes patient data and generates personalized treatment plans. The plans are integrated with IoT-enabled wearables that monitor IGF-1 levels and clinical symptoms in real-time. The system also includes a blockchain-based patient data management platform that ensures secure and transparent data sharing. The wearable device features a nanosensor array for detecting changes in IGF-1 levels, which is connected to an AI-powered analytics platform for real-time data analysis and personalized treatment recommendations. The system also utilizes a nanomaterial-based oral dosage form for delivering octreotide with tunable release kinetics to optimize bioavailability and minimize side effects
Novelty and Inventive Step
The new claims introduce the synergistic combination of AI, IoT, blockchain, and nanomaterials to create a more powerful system for treating acromegaly. This integration of distinct technologies provides a novel and non-obvious solution that improves treatment outcomes and patient care
Alternative Embodiments and Variations
Alternative embodiments of the system could include the use of different AI algorithms, various IoT devices, or different blockchain platforms. The system could also be adapted for treating other diseases or conditions, such as diabetes or hypertension
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and digital health. The system could be marketed as a comprehensive solution for acromegaly treatment, with potential partnerships with pharmaceutical companies, healthcare providers, and medical device manufacturers
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/08 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K9/4858 |
| A | A61 | A61K38/31 |
| A | A61 | A61P5/06 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology, pharmaceutical formulations, and digital health technologies focused on endocrine disorder treatment, specifically acromegaly management and drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A person with advanced training in pharmaceutical sciences, biotechnology, and digital health, possessing expertise in drug delivery mechanisms, medical device design, and AI-driven healthcare technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with existing pharmaceutical treatment methods represents a predictable evolution of medical care. The combination of AI, IoT, and blockchain with established octreotide treatment protocols provides a logical extension of known medical technology approaches. The PTD's innovations represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize patient monitoring and treatment personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,595 |
|---|---|
| Title | Method of treating diseases |
| Assignee(s) | Amryt Endo, Inc. |